Cargando…
Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
Immune checkpoint inhibitors (ICIs) are able to reactivate the immune system, thereby enhancing the anti‐tumor effects. However, over‐activated T cells may induce immune‐related adverse events (irAEs). Hematological irAEs are rarely reported which mainly represent monolineage cytopenia or pancytopen...
Autores principales: | Zhuang, Junling, Du, Jianhua, Guo, Xiaoxiao, Zhou, Jiaxin, Duan, Lian, Qiu, Wei, Si, Xiaoyan, Zhang, Li, Li, Yue, Liu, Xiaowei, Wang, Hanping, Zhou, Daobin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049514/ https://www.ncbi.nlm.nih.gov/pubmed/32017466 http://dx.doi.org/10.1111/1759-7714.13281 |
Ejemplares similares
-
Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019) -
Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019) -
Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections
por: Lu, Minya, et al.
Publicado: (2020) -
Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
por: Liu, Xiaowei, et al.
Publicado: (2020) -
Use of glucocorticoids in the management of immunotherapy‐related adverse effects
por: Wang, Hanping, et al.
Publicado: (2020)